Previous 10 | Next 10 |
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a...
Icosavax ( NASDAQ: ICVX ) said it began a phase 1 trial of its combination bivalent vaccine candidate against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), IVX-A12 in older adults. HMPV can cause upper and lower respiratory disease in peop...
- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage - - Phase 1 topline interim results expected in mid-2023 - - Phase 2 initiation planned to follow...
The following slide deck was published by Icosavax, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Icosavax, Inc. 2022 Q2 - Results - Earnings Call Presentation
Icosavax press release ( NASDAQ: ICVX ): Q2 GAAP EPS of -$0.57. Cash and cash equivalents, restricted cash, and short-term investments of $243.9M at end 2Q 2022. For further details see: Icosavax GAAP EPS of -$0.57
– Announced positive topline interim Phase 1/1b results for VLP vaccine candidate IVX-121 against respiratory syncytial virus (RSV) - – Icosavax plans to file an IND and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + human metapneumovirus (hMPV)...
Icosavax ( NASDAQ: ICVX ) will select a bivalent COVID-19 vaccine to move forward with in 2023 following an investigation in its monovalent COVID vaccine IVX-411. Phase 1/2b topline data for IVX-411 showed an immunologic response that was inconsistent with ex...
- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs - - Now focused on a bivalent strategy for COVID-19 candidate development displaying computationally engineered RBD antigens; provides opt...
SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a...
Gainers: Allena Pharmaceuticals ( ALNA ) +191% . Brickell Biotech ( BBI ) +78% . Decibel Therapeutics ( DBTX ) +35% . Cognition Therapeutics ( CGTX ) +26% . Akouos ( AKUS ) +20% . Fujian Blue Hat Interactive Entertainment Tec...
News, Short Squeeze, Breakout and More Instantly...
Shandong Weigao Group Medical Polymer Co. Ltd. - Class H (SHWGF) is expected to report for Q4 2023 Country Garden Holdings Co., Ltd. ADR (CTRYY) is expected to report for Q4 2023 Mondi Plc ADR (New) (MONDY) is expected to report for Q4 2023 Telecom Italia S.p.A. ADR - Preference Share...
NEW YORK, NY / ACCESSWIRE / February 1, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: AVROBIO, Inc. (NASDAQ:AVRO)'s merge...
2024-01-09 00:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...